A trial looking at dovitinib to treat advanced transitional cell cancer that has spread

Cancer type:

Bladder cancer
Kidney cancer
Transitional cell cancer

Status:

Results

Phase:

Phase 2

This trial was for people with transitional cell cancer that had spread into the surrounding tissue (locally advanced) or to another part of the body.

More about this trial

Transitional cells Open a glossary item (also called urothelial cells) are found throughout the urinary system Open a glossary item. You can get transitional cell cancer in the kidney, bladder or ureters.

Chemotherapy is used to treat advanced transitional cell cancer. But sometimes the cancer comes back after treatment (relapsed). Or it continues to grow during treatment (refractory). So doctors are always looking for new ways to treat advanced transitional cell cancer.

Dovitinib is a type of biological therapy called a tyrosine kinase inhibitor (TKI). It works by blocking messages to cells that tell them to grow and divide. So, dovitinib might stop cancer cells from growing and spreading.

The aims of this study were to find 

  • if dovitinib helped people with advanced transitional cell cancer
  • how safe it was for people with advanced transitional cell cancer

Summary of results

The trial team found that dovitinib didn’t work very well for people with advanced transitional cell carcinoma. 

This was a phase 2 trial. 44 people took part and everyone had dovitinib. 

There were 2 stages to this trial. At the end of the 1st stage the researchers looked at the overall number of people who had no sign of their cancer (complete response Open a glossary item) and whose cancer had shrunk (partial response Open a glossary item). This is the overall response rate. The trial would only continue into stage 2 if enough people’s cancer had responded. 

They found that only 1 person’s cancer had shrunk. So the decision was made to stop the trial. 

The worst side effects were 

  • a drop in blood cells
  • tiredness 
  • weakness and a lack of energy

The trial team concluded that dovitinib was safe for people with advanced transitional cell carcinoma. But by itself it didn’t work well enough. 
 
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr John Chester

Supported by

Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Novartis

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

6631

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Wendy took part in a new trial studying the possible side effect of hearing loss

A picture of Wendy

"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page